610
Views
5
CrossRef citations to date
0
Altmetric
Drug Evaluation

Relugolix for the treatment of uterine fibroids

, ORCID Icon, , , , , , , & show all
Pages 1667-1674 | Received 08 Dec 2019, Accepted 23 Jun 2020, Published online: 17 Jul 2020

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Tomoyuki Tatenuma & Hiroshi Miyamoto. (2023) Profile of Relugolix in the Management of Advanced Hormone-Sensitive Prostate Cancer: Design, Development, and Place in Therapy. Drug Design, Development and Therapy 17, pages 2325-2333.
Read now
Michał Ciebiera, Obianuju Sandra Madueke-Laveaux, Stepan Feduniw, Mara Ulin, Robert Spaczyński, Magdalena Zgliczyńska, Monika Bączkowska, Elżbieta Zarychta, Tomasz Łoziński, Mohamed Ali & Ayman Al-Hendy. (2023) GnRH agonists and antagonists in therapy of symptomatic uterine fibroids – current roles and future perspectives. Expert Opinion on Pharmacotherapy 24:16, pages 1799-1809.
Read now
Inmaculada Nicolás, María Ángeles Martínez-Zamora, Meritxell Gracia, Ana Carrion, Georgina Feixas, Laura Bernal, Lara Quintas, Mariona Rius, Camil Castelo-Branco & Francisco Carmona. (2021) Management of symptomatic uterine fibroids after ulipristal acetate suspension and identification of high risk patients for surgery at 6-months of follow-up. Gynecological Endocrinology 37:9, pages 831-835.
Read now

Articles from other publishers (2)

Daniel Ernesto Carvallo Ruiz, Elizabeth Natalia Martínez-Núñez & José Núñez-Troconis. (2022) Gynecological uses of GnRH antagonists: review article. Obstetrics & Gynecology International Journal 13:4, pages 226-238.
Crossref
Gizem Kayki-Mutlu & Martin C. Michel. (2021) A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. Naunyn-Schmiedeberg's Archives of Pharmacology 394:5, pages 839-852.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.